Drug management

Drug pricing & markets, value-based pricing, cost control, real-world evidence for safety and effectiveness

An Express Scripts analysis backs up industry claims that high-priced HIV medications may save money in the long run because they improve adherence.
The Value Proposition: PBM Mergers
Robert Calandra

Recent mergers didn’t quiet the growing frustration and concern employers, pharmacists, consumer advocates, state legislators, and some members of Congress have with the PBMs’ lack of transparency. There are still so many questions, and getting answers anytime soon will be a chore.

Q&A
Jennifer Graff
A conversation with Jennifer Graff, National Pharmaceutical Council VP
Richard Mark Kirkner
Implementation of a new framework would secure RWE’s role in the drug-approval process.
Women’s Health
Jan Greene
The pendulum has swung back and forth on hormone replacement therapy. Bespoke and supposed more ‘natural’ hormone combinations put together by compounding pharmacists have become popular. Mainstream endocrinologists see compounding as risky, partly because the practitioners who prescribe it may not see the dangers.
News & Commentary
Health care providers in the U.S. and Europe don’t know much about biosimilars, and what they think they know about them makes them wary, according to a review published recently in the Journal of Managed Care and Specialty Pharmacy.
News & Commentary
A real-world study of Neupogen (filgrastim) and its biosimilars didn’t find any clinical differences between the reference product and its biosimilars. But the researchers didn’t find any real cost savings, either. They chalked up the lack of savings to when the study was done—the data are from 2012 to 2017—and biosimilar nascency.
News & Commentary
Tinkering with reimbursement policies so providers have an incentive to prescribe biosimilars would help increase their acceptance. Two possible ways that commercial insurers can go about doing this are differential markup or fixed reimbursement.